Eric Lawitz, MD

Clinical Professor

Transplant Hepatologist

Texas Liver Institute Hepatologist

Dr. Lawitz is a Medical Director of the Texas Liver Institute and a Clinical Professor of Medicine at University of Texas Health Science Center in San Antonio, Texas. Dr. Lawitz received a B.S. from University of Illinois Chicago and M.D. from Rush Medical College. Dr. Lawitz received his postgraduate training in Gastroenterology/Hepatology at Brooke Army Medical Center and is board certified in the area of Gastroenterology/Hepatology.

Professional Background
Education
- 1999 - Fellowship - Gastroenterology - Brooks Army Medical Center, TX
- 1994 - Internship - Internal Medicine - Brooks Army Medical Center, TX
- 1993 - MD - Medicine - Rush Medical College, Chicago, IL
Highlights

11/2002
William Beaumont Clinical Research Award
03/2002
Cover Feature: Featured on cover of periodical "Hepatitis" 2002 Vol. 4 (2)
11/2001
Recognition of Investigator-Initiated Research: Recognizing Discover and Innovation in 2001: Milestone Award in Hepatitis C, Dallas, TX; awarded Milestone Award
07/2000
Lifetime Member: Listed in The National Registry of Who's Who
Research & Grants

Journal Article
1.Lawitz EJ. Diagnosis and management of telaprevir-associated rash. Gastroenterol Hepatol (N Y) 2011 Jul;7(7):469-471.
2.Lawitz EJ, ESTEBAN R, GORDON S, MARCELLIN P, VIERLIN J, ZEUZEM S, POORDAD F, BOPARAI N, BURROUGHS M, ALBRECHT J, BRASS C, BACON B. Utility of historical data compared to lead-in response in predicting sustaned virologic response to non-responders and relapsers to Peginterferon/Ribavirin when re-treated with Boceprevir Peginterferon Alfa-2B/Ribavirin(P/R) Journal of Hepatology 2011;54(1)
Clinical
Publications

Lawitz EJ, JACOBSON I, GODOFSKY E, FOSTER G, FLISIAK R, BENNETT M, RYAN M, HINKLE J, SIMPSON J, McHUTCHISON J, OLDACH D. A phase 2B trial comparing 24 to 48 weeks treatment with Tegobuvir(GS-9190)/PEG/RBV TO 48 weeks treatment with PEG/RBV for chronic genotype-1 HCV Infection Journal of Hepatology 2011;54(1)
Lawitz EJ, Long W, Younossi Z, Kotsev I, Takov D, Tchernev K, Rigney A, Ghalib R, Stoinov S, Balabanska R, Mehra P, Krastev Z. Timing and frequency of depression during HCV-treatment with controlled-release IFNA2B(CR2B) VS pegylated-IFNA2B(PEG2B): Results from Select-2, A randomized open label 72 week comparison in 116 treatment naive patients with Genotype-1 HCV. Journal of Hepatology 2011;54(1)

Eric Lawitz, MD

Education

Highlights